Quillivant XR
ApprovedSmall molecule
PfizerQuillivant XR is one of 67 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
102 competitors in Attention Deficit Hyperactivity Disorder
#DrugCompanyPhaseTrials
1Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Catapres
Boehringer IngelheimPhase 3
Ambien
PPurdue Pharma LP
Phase 3
OROS Oxybutynin
Johnson & JohnsonPhase 3
Provigil
NNuvo Research GmbH
Phase 3
Sunosi
AAxsome Therapeutics, Inc.
Phase 3
Ritalin
PfizerPhase 3
Cymbalta
Alnylam PharmaceuticalsPhase 2
Adderall-XR
NNew River Pharmaceuticals
Phase 3
Concerta
Johnson & JohnsonPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Down syndrome1 trial
Evaluating Treatment of ADHD in Children with Down Syndrome
Recruiting·—·Phase 4·NCT04219280·100 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Quillivant XR. EMBL-EBI & Wellcome Sanger Institute.
- [4]